Takeda Pharmaceutical Company Limited (NYSE: TAK) has inked an agreement with Evotec SE. Both the firms have made a strategic partnership with the sole aim to discover and create RNA targeting small molecule therapeutics for extremely attractive targets that are difficult to deal with through more traditional methods.
As per the partnership deal, Evotec and TAK will mutually create and discover small molecules pursuing a range of RNA targets associated with R&D areas of Takeda. The partnership will utilize the broad RNA targeting platform of Evotec to make the best possible to discover encouraging RNA sequences to target with small-molecule ligands that can be created into possibly first-in-class therapeutics.
In accordance with the partnership deal, Evotec will obtain a substantial research grant and will be entitled to receive detection, pre-clinical, experimental, industrial, and sales milestone consideration of up to US$ 160 m per program. Besides, Evotec is eligible to levels royalties on net sales of any products derived from the partnership.
Takeda disclosed that it has found out that targeting RNA with small-molecule is an encouraging new approach that has enormous potential for many necessary medicines for sufferers through transforming traditionally undruggable objectives.